BioNTech SE
NASDAQ:BNTX
BioNTech SE
NASDAQ:BNTX
Price:
92.2 USD
-0.09%
Market Closed
Updated:
May 16, 2024
BioNTech SE
Revenue
|
BioNTech SE
Revenue Peer Comparison
Comparables:
MOR
CVAC
IMTX
BIO
FYB
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
BioNTech SE
NASDAQ:BNTX
|
Revenue
€3.8B
|
CAGR 3-Years
99%
|
CAGR 5-Years
97%
|
CAGR 10-Years
N/A
|
|
|
MorphoSys AG
XETRA:MOR
|
Revenue
€203.5m
|
CAGR 3-Years
18%
|
CAGR 5-Years
18%
|
CAGR 10-Years
10%
|
|
|
CureVac NV
NASDAQ:CVAC
|
Revenue
€53.8m
|
CAGR 3-Years
3%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Revenue
€54m
|
CAGR 3-Years
20%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Revenue
€684.6m
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
3%
|
|
|
Formycon AG
XETRA:FYB
|
Revenue
€77.7m
|
CAGR 3-Years
31%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
BioNTech SE
Revenue Breakdown
Breakdown by Geography
BioNTech SE
BioNTech SE
|
Total Revenue:
3.8B
EUR
|
|
United States:
3B
EUR
|
|
Germany:
482.7m
EUR
|
Breakdown by Segments
BioNTech SE
BioNTech SE
|
Total Revenue:
3.8B
EUR
|
|
Commercial:
3.8B
EUR
|
|
Research And Development:
3.5m
EUR
|
See Also
What is BioNTech SE's Revenue?
Revenue
3.8B
EUR
3.8B
EUR
Based on the financial report for Dec 31, 2023, BioNTech SE's Revenue amounts to 3.8B EUR.
What is BioNTech SE's Revenue growth rate?
Revenue CAGR 5Y
97%
97%
Over the last year, the Revenue growth was -78%. The average annual Revenue growth rates for BioNTech SE have been 99% over the past three years , 97% over the past five years .
You don't have any saved screeners yet
